Distinct pathways utilized by METTL3 to regulate antiviral innate immune response.

Methyltransferase-like 3 (METTL3), the core methyltransferase for -methyladenosine (m6A), plays a crucial role in innate immunity by introducing m6A modifications on viral or host RNAs. Despite its well-established catalytic function in m6A deposition, the broader role of METTL3 in immune regulation remains unclear. Here, we uncovered that EV71 infection enhanced METTL3 expression in interferon (IFN)-deficient Vero and IFN-proficient rhabdomyosarcoma (RD) cells by modulating transcription and post-translational modification, respectively.

New cytotoxic compounds from (Kom.) Nakai.

Twenty-one compounds were isolated and identified from the ethanol extract of (Kom.) Nakai, including two new compounds ( and ), a new artificial product () and eighteen known compounds (). Compounds and were isolated from for the first time.

RNF112, whose transcription is regulated by KLF4, inhibits colorectal cancer growth via promoting ubiquitin-dependent degradation of NAA40.

Background: RING finger protein 112 (RNF112) exerts a key role in human tumors. However, its biological function in colorectal cancer (CRC) has not been discussed. We aimed to explore the function and molecular mechanism of RNF112 in CRC.

Impact of 2,4-di-tert-butylphenol on pancreatic lipase activity in emulsions: Multispectral, molecular docking, and in vitro digestion analysis.

2,4-di-tert-butylphenol (2,4-DTBP) is an additive used in food packaging. The inhibitory effects of 2,4-DTBP on pancreatic lipase (PL) were investigated in this study. Kinetic analysis indicated that 2,4-DTBP competitively and reversibly inhibited PL activity.

PlexinD1 is a driver and a therapeutic target in advanced prostate cancer.

Aggressive prostate cancer (PCa) variants associated with androgen receptor signaling inhibitor (ARSI) resistance and metastasis remain poorly understood. Here, we identify the axon guidance semaphorin receptor PlexinD1 as a crucial driver of cancer aggressiveness in metastatic castration-resistant prostate cancer (CRPC). High PlexinD1 expression in human PCa is correlated with adverse clinical outcomes.